
Yu Deng
Articles
-
1 month ago |
nature.com | Weijie Zheng |Xingyue Ma |Zhentao Pang |Hongying Chen |Chunyan Zheng |Jianyi Liu | +9 more
Polar skyrmions have demonstrated rich physics and exotic properties for developing novel functionalities. However, so far, skyrmion nanodomains exist only in a few material systems, such as ferroelectric/dielectric superlattices, free-standing PbTiO3/SrTiO3 epitaxial bilayers and ultrathin Pb(Zr,Ti)O3/SrTiO3/Pb(Zr,Ti)O3 sandwiches. These heterostructures are fabricated with elaborately designed boundary conditions to meet the delicate energy balance for stabilizing topological phases. This requirement limits the broad applications of skyrmions in electronic devices. Here we show widespread skyrmion nanodomains in ferroelectric–antiferroelectric solid solutions, composed of ferroelectric PbTiO3 and one antiferroelectric PbSnO3 (Pb(Ti1–xSnx)O3), PbHfO3 (Pb(Ti1–xHfx)O3) or PbZrO3 (Pb(Ti1–xZrx)O3). The skyrmionic textures are formed by engineering dipole–dipole and antiferrodistortive–dipole couplings in competition between ferroelectric and antiferroelectric polar orderings, allowing the stabilization of topological phases. A phase diagram is built for the three solid solution series, revealing the stabilization regions of skyrmion nanodomains. In addition, the non-trivial domains also exhibit improved switching character, reversible writing/erasure and long-term retention for the electrical manipulation of polar configurations. These findings open an avenue for the investigation and exploitation of polar skyrmions in ferroelectric-based materials, providing opportunities in topological electronics. Polar skyrmions are of interest for nanoelectronics due to their exotic properties. However, so far, these are metastable states requiring a delicate balance of boundary conditions to form in heterostructures. In ferroelectric and antiferroelectric solid solutions, skyrmionic textures are observed to form in both bulk and film.
-
Oct 16, 2024 |
science.org | Jourdan Ewoldt |Olivia Gozel |Sebastian Quaade |Yu Deng
Abstractc-di-GAMP was first identified in bacteria to promote colonization, while mammalian 2′3′-cGAMP is synthesized by cGAS to activate STING for innate immune stimulation. However, 2′3′-cGAMP function beyond innate immunity remains elusive. Here, we report that 2′3′-cGAMP promotes cell migration independent of innate immunity. 2′3′-cGAMP interactome analysis identifies the small GTPase Rab18 as a 2′3′-cGAMP binding partner and effector in cell migration control.
-
Aug 2, 2024 |
digitalcommons.library.tmc.edu | Yu Deng |Lacey P. Gleason |Adam Culbertson |Xiaotian Chen
AbstractVariation in availability, format, and standardization of patient attributes across health care organizations impacts patient-matching performance. We report on the changing nature of patient-matching features available from 2010-2020 across diverse care settings. We asked 38 health care provider organizations about their current patient attribute data-collection practices. All sites collected name, date of birth (DOB), address, and phone number.
-
Jul 8, 2024 |
pubs.rsc.org | Jiahao Pan |Yuchen Zhang |Zhentao Pang |Yu Deng
Revealing the Correlation between Size, Structure, and Fluorescence Enhancement in Ag@Au Nanocube Clusters: A High-Content Platform Approach This work presents a high-content platform for investigating the critical interplay between nanoparticle cluster size, structure, and plasma-enhanced fluorescence at single particle level.
-
Jun 21, 2024 |
nature.com | Yu Deng
AbstractEwing sarcoma is a pediatric bone and soft tissue tumor treated with chemotherapy, radiation, and surgery. Despite intensive multimodality therapy, ~50% patients eventually relapse and die of the disease due to chemoresistance. Here, using phospho-profiling, we find Ewing sarcoma cells treated with chemotherapeutic agents activate TAM (TYRO3, AXL, MERTK) kinases to augment Akt and ERK signaling facilitating chemoresistance.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →